Research and development collaborations

Working together

By leveraging our expertise alongside research partners, healthcare and clinical experts, industry peers, patients, and patient advocacy groups, our goal is to discover and develop oncology therapies that can potentially make a transformational improvement in cancer treatment.

Through progressive science and research, we aim to shape the way cancer is treated.

We are committed to combining the best talent, thinking, and resources to foster innovation on behalf of people affected by cancer. That's why our internal research efforts are balanced with external collaborations across the highest levels of industry, academia, and government.

Tackling cancer together

Our pioneering oncology research and development may shape the way cancer is treated. See how the AbbVie team is taking on the challenges of cancer.

Play video

Joining forces to accelerate our oncology portfolio

Pharmacyclics is an AbbVie company focused on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases. Pharmacyclics and its partner, Janssen Biotech, developed and commercialize IMBRUVICA® (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). AbbVie's acquisition of Pharmacyclics enables us to build a strong leadership position in hematological oncology, where there is significant patient need.

Partnering with MD Anderson to advance immunotherapy

AbbVie's recent collaboration with the immunotherapy platform at the University of Texas MD Anderson Cancer Center will empower us to find new ways to unleash the immune system's potential to fight cancer.

Pairing MD Anderson's cutting-edge preclinical, translational, and clinical capabilities with AbbVie's innovative discovery and development programs accelerates our ability to deliver new therapies that can help transform the lives of people affected by cancer.

Facilitating deeper collaboration in the oncology community

We recognize the value of every voice and mind in the oncology community. We hope that sharing our knowledge and science with the larger professional oncology community will encourage curiosity and healthy dialogue, the outcome of which may lead to greater opportunities to help address areas of need on behalf of people affected by cancer.

Strategic Collaborations

AbbVie is dedicated to tackling the toughest challenges in oncology, through our own research and through strategic collaborations with external organizations, in order to advance our science.

These partnerships are developed to pursue two critical goals: discovering and developing new medicines, and improving patient outcomes. Our partners share this patient-focused commitment to help address areas of unmet need in oncology.

We are proud to work with a range of organizations, including the select list below, to make a remarkable impact on the lives of people affected by cancer around the world:

Genentech
Bristol-Myers Squibb
Infinity
The University of Texas MD Anderson Cancer Center
The University of Chicago Medicine
National Foundation for Cancer Research (NFCR)
National Cancer Institute (NCI)
Center for Advanced Preclinical Research (CAPR)

Visit AbbVie.com/Oncology to view our full list of collaboration partners.

Need more information?

Explore Careers

Contact Medical Information

For All Other Information